Leerink Partnrs upgraded shares of PureTech Health (NASDAQ:PRTC – Free Report) to a strong-buy rating in a research report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for PureTech Health’s FY2024 earnings at ($4.27) EPS, FY2025 earnings at ($4.84) EPS and FY2026 earnings at ($3.77) EPS.
Separately, Leerink Partners started coverage on PureTech Health in a research report on Monday. They set an outperform rating and a $45.00 price objective on the stock.
Read Our Latest Stock Analysis on PRTC
PureTech Health Stock Up 0.5 %
Institutional Trading of PureTech Health
A hedge fund recently bought a new stake in PureTech Health stock. AWM Investment Company Inc. acquired a new stake in PureTech Health plc (NASDAQ:PRTC – Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,900 shares of the company’s stock, valued at approximately $197,000. 0.04% of the stock is currently owned by hedge funds and other institutional investors.
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
- Five stocks we like better than PureTech Health
- What Does a Stock Split Mean?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- What Does Downgrade Mean in Investing?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Retail Stocks Investing, Explained
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.